Table 2.
Univariate and multivariate analysis of contributing factors to humoral immune response after vaccination in patients with common variable immunodeficiency phenotype.
| Variable | Humoral immune response present (n = 20) | Deficient Humoral immune response (n = 8) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| OR | p | eβ | p | |||
| Age, yr; median (IQR) | 48.5 (39.5−66) | 62.5 (45−72.5) | n.a. | 0.165 | n.i. | 0.296 |
| Lymphocytes, x109 cells/L; median (IQR) | 1.43 (1.04−2.52) | 1.38 (0.78−1.87) | n.a. | 0.469 | n.i. | 0.701 |
| Albumin, g/L; median (IQR) | 45.6 (43.8−47.4) | 42.5 (39.0−47.8) | n.a. | 0.281 | n.i. | 0.537 |
| Creatinine, μmol/L; median (IQR) | 71 (56−81.5) | 67.5 (62.5−82.5) | n.a. | 0.980 | n.i. | 0.997 |
| Immunoglobulin G, mg/L; median (IQR) | 8853 (6011−10146) | 7496 (7150−10304) | n.a. | 0.823 | n.i. | 0.716 |
| Immunoglobulin M, mg/L; median (IQR) | 294 (87−459) | 71.5 (50−144) | n.a. | 0.099 | n.i. | 0.214 |
| Immunoglobulin A, mg/L; median (IQR) | 135 (50−955) | 50 (50−50) | n.a. | 0.043 | n.i. | 0.560 |
| CD3+, x106/L; median (IQR) | 1016 (847−1837) | 1205 (663−1802) | n.a. | 0.823 | Ex.col. | Ex.col. |
| CD3+, %; median (IQR) | 78.5 (72.5−82.5) | 87.0 (81.0−93.5) | n.a. | 0.008 | n.i. | 0.264 |
| CD3+CD4+, x106/L; median (IQR) | 648 (458−1061) | 424 (330−622) | n.a. | 0.055 | Ex.col. | Ex.col. |
| CD3+CD4+, %; median (IQR) | 43.5 (36.5−50.0) | 30.5 (25.0−37.5) | n.a. | 0.033 | n.i. | 0.492 |
| CD3+CD4+, < 200x106/L; n (%) | 0 (0.0) | 1 (12.5) | n.a. | 0.286 | Ex.col. | Ex.col. |
| CD3+CD4+CD45RA, < 10%; n (%) | 9 (45.0) | 5 (62.5) | 0.491 (0.091−2.636) | 0.678 | n.i. | 0.390 |
| CD3+CD8+, x106/L; median (IQR) | 385 (250−586) | 642 (352−1228) | n.a. | 0.237 | Ex.col. | Ex.col. |
| CD3+CD8+, %; median (IQR) | 26.5 (18.0−35.5) | 50.5 (42.0−56.0) | n.a. | 0.018 | n.i. | 0.350 |
| (CD3+CD4+)/(CD3+CD8+), 1; median (IQR) | 1.80 (1.07−2.66) | 0.63 (0.46−0.82) | n.a. | 0.019 | Ex.col. | Ex.col. |
| NK (CD3-CD16+CD56+), x106/L; median (IQR) | 147 (75.5−196) | 87.5 (23−133) | n.a. | 0.199 | n.i. | 0.285 |
| NK (CD3-CD16+CD56+), %; median (IQR) | 7.0 (6.0−13.5) | 5.0 (3.0−15.0) | n.a. | 0.469 | Ex.col. | Ex.col. |
| CD19+, x106/L; median (IQR) | 163 (86.7−267) | 10 (0−51) | n.a. | <0.001 | Ex.col. | Ex.col. |
| CD19+, %; median (IQR) | 11.0 (8.0−13.5) | 1.0 (0.0−7.0) | n.a. | 0.008 | Ex.col. | Ex.col. |
| CD19+, ≤ 1%; n (%) | 0 (0.0) | 6 (75.0) | n.a. | <0.001 | n.i. | 0.304 |
| Switched memory B cells (CD19+CD27+IgD-IgM-), ≤ 2%; n (%) | 7 (35.0) | 8 (100.0) | n.a. | 0.007 | n.i. | 0.607 |
| Transitional B cells (CD19+CD24hiCD27-CD38hi), < 9%; n (%) | 19 (95.0) | 6 (75.0) | n.a. | 0.385 | n.i. | 0.239 |
| Activated B cells (CD19+CD21loCD38lo), > 10%; n (%) | 1 (5.0) | 0 (0.0) | n.a. | 1.000 | n.i. | 0.992 |
| Absent haemagglutinins; n (%) | 5 (26.3) | 3 (37.5) | 0.595 (0.103−3.454) | 0.658 | n.i. | 0.896 |
| Salmonella Typhi M vaccine, deficient?? response; n (%) | 17 (85.0) | 8 (100.0) | n.a. | 0.629 | n.i. | 0.986 |
| Number of days between the vaccine second dose and blood extraction for analysis; median (IQR) | 28 (28−33) | 32.5 (28−40.5) | n.a. | 0.566 | n.i. | 0.244 |
| Immunoglobulin Replacement Therapy, yes; n (%) | 15 (75.0) | 8 (100.0) | n.a. | 0.281 | n.i. | 0.604 |
IQR, interquartile range; OR, odds ratio; eβ, multivariate odds ratio; n.a, not applicable; n.i., not included in the binary logistic regression equation; Ex.col., variable excluded in the multivariate analysis to avoid multicollinearity.
Significant p-values are in bold.